GURUFOCUS.COM » STOCK LIST » USA » NAS » OncoCyte Corp (NAS:OCX) » Definitions » Cash Flow from Operations
Switch to:

OncoCyte (NAS:OCX) Cash Flow from Operations

: $-42.99 Mil (TTM As of Sep. 2022)
View and export this data going back to 2015. Start your Free Trial

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Sep. 2022, OncoCyte's Net Income From Continuing Operations was $-9.33 Mil. Its Depreciation, Depletion and Amortization was $1.37 Mil. Its Change In Working Capital was $-0.54 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $3.18 Mil. And its Cash Flow from Others was $-6.03 Mil. In all, OncoCyte's Cash Flow from Operations for the three months ended in Sep. 2022 was $-11.35 Mil.


OncoCyte Cash Flow from Operations Historical Data

The historical data trend for OncoCyte's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Operations
Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.39 -11.65 -19.72 -25.98 -35.94

OncoCyte Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cash Flow from Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.98 -7.07 -13.28 -11.29 -11.35

OncoCyte Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

OncoCyte's Cash Flow from Operations for the fiscal year that ended in Dec. 2021 is calculated as:

OncoCyte's Cash Flow from Operations for the quarter that ended in Sep. 2022 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte  (NAS:OCX) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

OncoCyte's net income from continuing operations for the three months ended in Sep. 2022 was $-9.33 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

OncoCyte's depreciation, depletion and amortization for the three months ended in Sep. 2022 was $1.37 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

OncoCyte's change in working capital for the three months ended in Sep. 2022 was $-0.54 Mil. It means OncoCyte's working capital declined by $0.54 Mil from Jun. 2022 to Sep. 2022 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

OncoCyte's cash flow from deferred tax for the three months ended in Sep. 2022 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

OncoCyte's cash from discontinued operating Activities for the three months ended in Sep. 2022 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

OncoCyte's asset impairment charge for the three months ended in Sep. 2022 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

OncoCyte's stock based compensation for the three months ended in Sep. 2022 was $3.18 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

OncoCyte's cash flow from others for the three months ended in Sep. 2022 was $-6.03 Mil.


OncoCyte Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of OncoCyte's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (NAS:OCX) Business Description

OncoCyte logo
Industry
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Executives
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund director C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Gisela Paulsen officer: Chief Operating Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas T. Ross officer: Chief Medical Officer 15 CUSHING, IRVINE CA 92618
Tony T Kalajian officer: SVP-Chief Accounting Officer 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Padma Sundar officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008

OncoCyte (NAS:OCX) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership